abstract |
The present invention features a compound of formula I: nor a pharmaceutically acceptable salt thereof, where R 1 n, R 2 n, R 3 n, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof. |